- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01902732
Endoscopic Lung Volume Reduction After Catheter-based CV Measurement in Patients With Heterogeneous Emphysema and Complete Interlobar Fissures
July 15, 2013 updated by: Felix JF Herth, Heidelberg University
Bronchoscopic Volume Reduction With Valve Implants After Analysis of Interlobar Fissure Integrity and Measurement of Collateral Ventilation in Patients With Severe, Heterogeneous Emphysema
This clinical trial evaluates the impact of catheter-based measurement of interloabr collateral ventilation prior to endoscopic lung volume reduction in patients with hetereogeneous emphysema and complete interlobar fissures in high resolution computed tomography.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
50 patients (25 per center) with heterogeneous lung emphysema with indication for endoscopic lung volume reduction by valve implantation will be prospectively included in the study.
Heterogeneity of emphysema and fissure completeness of the relevant lobe will be proven from high resolution computed tomography (HRCT) prior to enrolment in the study.
Fissure integrity will be analyzed by a core radiology.
If fissure completeness is proved, patients will be enrolled in the study.
All recruited patients will additionally receive a collateral ventilation measurement by using the Chartis® Pulmonary Assement System during a flexible bronchoscopy.
Depending on the results of this measurement, patients are divided in two parallel arms: A: complete fissure integrity and low collateral ventilation (CV negative) B: complete fissure integrity and high collateral ventilation (CV positive) Following the CV measurement, each patient will receive valve therapy.
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Grosshansdorf, Germany, 22927
- Recruiting
- LungenClinic Grosshansdorf
-
Contact:
- Klaus Rabe
- Email: k.f.rabe@ungenclinic.de
-
Sub-Investigator:
- Rabe Klaus, Prof. Dr. med.
-
Großhansdorf, Germany, 22927
- Recruiting
- LungenClinic Grosshansdorf
-
Contact:
- Henrik Watz, PD Dr. med.
- Email: H.Watz@pulmoresearch.de
-
Sub-Investigator:
- Henrik Watz, PD Dr. med.
-
Heidelberg, Germany, 69126
- Recruiting
- Thoraxklinik Heidelberg
-
Contact:
- Felix JF Herth, MD
- Phone Number: 1200 +49 6221 396
- Email: Felix.Herth@thoraxklinik-heidelberg.de
-
Heidelberg, Germany, 69126
- Recruiting
- Thoraxklinik
-
Contact:
- Ralf Eberhardt, MD
- Phone Number: 8204 +49 6221 396
- Email: Ralf.Eberhardt@thoraxklinik-heidelberg.de
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- written informed consent
- ability to understand the importance of adherence to study treatment and the study protocol and willing to follow all study requirements
- severe lung emphysema (FEV1<45%, RV>150%, TLC>100%)
- pO2>60 mmHg with 4l O2, pCO2 < 60 mmHg at rest
- heterogeneous lung emphysema diagnosed with HRCT and perfusion scintigraphy
- confirmed heterogeneity by YACTA®
- disclosure of parallel channels through relevant interlobar fissures
- age > 30 years
- stable COPD without exacerbation 8 weeks prior to screening
- dose of cortisone< 20 mg prednisone or equivalent OCS
- non-smoker or ex-smoker who stopped smoking for at least 4 months prior to the screening visit
- current CoHb < 2,5%
Exclusion Criteria:
- BMI < 18 mg/kg2
- significant bronchiectasis with sputum production of 4 tablespoons/day
- 6-minute-walk distance < 150 m
- myocardial infarction within 6 weeks prior screening visit
- decompensated heart failure
- cardiomyopathy with moderate or severe restricted LVF
- long-term medication with Clopidogrel
- status after lung resection (Lobectomy/Pneumonectomy)
- existing pregnancy
- female subjects of child-bearing potential without acceptable forms of contraception
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Implantation of valves (IBV)
Following catheter-based measurement of collaertal ventilation, each patient is treated by a complete occlusion of the targeted lobe by intrabronchial valves.
|
Implantation of intrabronchial valves in the most emphysematous destroyed and hyperinflated lung lobe improves the elastic recoisl of the samll airways by a reduction in lung volume and thus leading to more ergonomic breathing mechanics and diaphragm function.
This positive effect is observed particularly in patients with low interlobar collateral ventilation that can be quantified by CT fissure analysis and/or catheter-based measurement.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Improvement on pulmonary function
Time Frame: 12 months
|
Development of lung function parameters FEV1 and RV/TLC.
Increase of FEV1 of 15% and decrease of RV/TLC of 10% compared to baseline will be considered as clinically significant.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of safety and efficacy
Time Frame: 12 months
|
Safety:
Efficacy:
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2013
Primary Completion (Anticipated)
December 1, 2014
Study Registration Dates
First Submitted
June 13, 2013
First Submitted That Met QC Criteria
July 15, 2013
First Posted (Estimate)
July 18, 2013
Study Record Updates
Last Update Posted (Estimate)
July 18, 2013
Last Update Submitted That Met QC Criteria
July 15, 2013
Last Verified
July 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Protocol G1.0.- 16.02.2012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heterogeneous Emphysema
-
Pulmonx CorporationCompletedCOPD | Heterogeneous EmphysemaNetherlands, Sweden, United Kingdom, Germany, France, Belgium
-
Royal Brompton & Harefield NHS Foundation TrustCompletedHeterogeneous EmphysemaUnited Kingdom
-
Pulmonx CorporationCompleted
-
Pulmonx CorporationRecruitingEmphysema or COPD | Emphysema, PulmonarySpain, Germany, Italy, Australia
-
Pulmonx CorporationActive, not recruiting
-
University Hospital, Strasbourg, FranceUnknownDNA Sequencing | Diagnosis of Genetic Diseases of Heterogeneous OriginFrance
-
Aeris TherapeuticsCompleted
-
University Medical Center GroningenCompletedEmphysema or COPDNetherlands
-
University Medical Center GroningenRecruitingEmphysema or COPDNetherlands
-
Aeris TherapeuticsCompleted
Clinical Trials on Implantation of valves (IBV)
-
Heidelberg UniversityTerminatedHereditary Emphysema (Alpha 1-antitrypsin Deficiency)Germany
-
Heidelberg UniversityCompleted
-
Heidelberg UniversitySpiration, Inc.UnknownPulmonary EmphysemaGermany
-
Ohio State UniversitySpiration, Inc.WithdrawnManagement of BPF (Bronchopleural Fistulae)United States
-
China National Center for Cardiovascular DiseasesActive, not recruitingAortic Stenosis | Ascending Aortic DilatationChina
-
Fondazione IRCCS Policlinico San Matteo di PaviaUniversity of PaviaRecruitingCalcific Aortic Valve DiaseaseItaly
-
Heidelberg UniversityAsklepios Kliniken Hamburg GmbH; Lung Clinic Hemer; Otto Wagner HospitalUnknown
-
Centre Hospitalier Universitaire, AmiensRecruiting
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Boston Scientific CorporationActive, not recruitingVentricular ArrhythmiasUnited States, United Kingdom, Netherlands, Germany, Denmark, Czechia
-
Peking University Third HospitalUnknown